Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 3/20 | 0.68 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 12/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | GNA15 | P30679 | 1/20 | 0.55 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15761745 | 0.88 | HIF1A (0.65) | HIF1ASENP1FFAR1CA1CA2 | |
| SCHEMBL15761753 | 0.88 | HIF1A (0.85) | HIF1ASENP1CA1CA2HDAC8 | |
| SCHEMBL28218801 | 0.84 | MRGPRX4 (0.61) | HIF1ASENP1FFAR1CA1CA2 | |
| SCHEMBL14878552 | 0.83 | HIF1A (0.54) | HIF1ASENP1FFAR1GNA15PTGER3 | |
| SCHEMBL15761776 | 0.83 | HIF1A (0.69) | HIF1ASENP1FFAR1CA1CA2 | |
| SCHEMBL8005946 | 0.82 | HIF1A (0.53) | HIF1ASENP1FFAR1HDAC8 | |
| SCHEMBL15761744 | 0.82 | HIF1A (0.67) | HIF1ASENP1CA1CA2HDAC8 | |
| SCHEMBL521860 | 0.81 | AKR1C3 (0.68) | HDAC8 | |
| SCHEMBL15761730 | 0.81 | HIF1A (0.65) | HIF1ASENP1FFAR1CA1CA2 | |
| SCHEMBL15761741 | 0.81 | HIF1A (0.65) | HIF1ASENP1CA1CA2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1115693-B9 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO CO (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1115693-B1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO CO (US) | 2007-05-02 | — | — | EP | disclosed |
| US-6765023-B2 | SUCH AS 3-((3-(3-TRIFLUOROMETHOXYPHENOXY)PHENYL)((3-(1,1,2,2-TETRAFLUOROETHOXY) -PHENYL)METHYL) AMINO)-1,1,1-TRIFLUORO-2-PROPANOL FOR TREATING CARDIOVASCULAR DISORDERS AND DYSLIPIDEMIA | PFIZER, INC. | 2004-07-20 | — | — | US | disclosed |
| US-6723753-B2 | TREATING ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES. | PHARMACIA CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-6710089-B2 | ATHEROSCLEROSIS; CARDIOVASCULAR DISORDERS; ANTICHOLESTEROL AGENTS | PHARMACIA CORPORATION | 2004-03-23 | — | — | US | disclosed |
| US-6699898-B2 | METHOD OF TREATING CORONARY ARTERY DISEASE OR OTHER CETP-MEDIATED DISORDERS IN A SUBJECT BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND OF ONE OF CLAIMS | PHARMACIA CORPORATION GLOBAL PATENT DEPARTMENT | 2004-03-02 | — | — | US | disclosed |
| US-6696435-B2 | FOR TREATING ATHEROSCLEROSIS, OTHER CORONARY ARTERY DISEASES; 3-((3-(3-TRIFLUOROMETHOXYPHENOXY)PHENYL)((3-(1,1,2,2-TETRAFLUOROETHOXY) -PHENYL)METHYL) AMINO)-1,1,1-TRIFLUORO-2-PROPANOL FOR EXAMPLE | PHARMACIA CORPORATION | 2004-02-24 | — | — | US | disclosed |
| US-6696472-B2 | TREATING ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES | PHARMACIA CORPORATION | 2004-02-24 | — | — | US | disclosed |
| US-6683099-B2 | FOR THERAPY OF ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES | PHARMACIA CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-6677379-B2 | SUCH AS 3-((3-(3-TRIFLUOROMETHOXYPHENOXY)PHENYL)((3-(1,1,2,2-TETRAFLUOROETHOXY) -PHENYL)METHYL) AMINO)-1,1,1-TRIFLUORO-2-PROPANOL FOR TREATMENT OF CORONARY ARTERY DISEASE | PHARMACIA CORPORATION | 2004-01-13 | — | — | US | disclosed |
| US-6458803-B1 | COMPOSITIONS AND METHODS FOR TREATING ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES. PREFERRED TERTIARY-HETEROALKYLAMINE COMPOUNDS ARE SUBSTITUTED N-PHENYL-N-HETEROARALKYL AMINOALCOHOLS. A PREFERRED SPECIFIC | G.D. SEARLE & CO. | 2002-10-01 | — | — | US | disclosed |
| US-6458849-B1 | METHOD OF TREATING OR PREVENTING A CEIP-MEDIATED DISORDER IN A SUBJECT BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND FOR STROKES | G.D. SEARLE & CO. | 2002-10-01 | — | — | US | disclosed |
| US-6458852-B1 | A METHOD OF TREATING OR PREVENTING A CETP-MEDIATED DISORDER IN A SUBJECT BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. | 2002-10-01 | — | — | US | disclosed |
| US-6455519-B1 | TREATING ATHEROSCLEROSIS AND CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. | 2002-09-24 | — | — | US | disclosed |
| US-6451830-B1 | Use of substituted N,N-disubstituted non-fused heterocyclo amino compounds for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2002-09-17 | — | — | US | disclosed |
| US-6451823-B1 | Use of substituted N-phenoxy-N-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2002-09-17 | — | — | US | disclosed |
| US-6448295-B1 | TREATING CARDIOVASCULAR DISEASE; ATHEROSCLEROSIS, DYSLIPIDEMA HYPERCHOLESTEROLAEMIA; DECREASING CONCENTRATIONS OF LOW DENSITY LIPOPROTEIN AND RAISING LEVEL OF HIGH DENSITY LIPOPROTEIN | G.D. SEARLE & CO. | 2002-09-10 | — | — | US | disclosed |
| US-20020120011-A1 | Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-08-29 | — | — | US | disclosed |
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120011-A1 | Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, PCTP, DBI | HIF1A 2573/4885SENP1 1124/4885FFAR1 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.